Doris Benbrook to Tamoxifen
This is a "connection" page, showing publications Doris Benbrook has written about Tamoxifen.
Connection Strength
0.375
-
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec; 119(3):444-50.
Score: 0.344
-
Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016 Jan; 27(1):e8.
Score: 0.031